124 related articles for article (PubMed ID: 27046053)
1. Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study.
Minig L; Patrono MG; Cárdenas-Rebollo JM; Martin Marfil P; Rodriguez-Tabares V; Chuang L
Gynecol Obstet Invest; 2016; 81(6):497-503. PubMed ID: 27046053
[TBL] [Abstract][Full Text] [Related]
2. The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study.
Buda A; Ghelardi A; Fruscio R; Guelfi F; La Manna M; Dell'Orto F; Milani R
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():156-8. PubMed ID: 26765122
[TBL] [Abstract][Full Text] [Related]
3. [Interest of a thrombin and fibrinogen combipatch in preventing breast cancer seroma after lymph node dissection].
Vinchant M; Bonneau C; Lesavre M; Akerman G; Raiffort C; Barranger E; Bricou A
Gynecol Obstet Fertil; 2013 Oct; 41(10):583-7. PubMed ID: 24139816
[TBL] [Abstract][Full Text] [Related]
4. The use of a surgical patch in the prevention of lymphoceles after extraperitoneal pelvic lymphadenectomy for prostate cancer: a randomized prospective pilot study.
Simonato A; Varca V; Esposito M; Venzano F; Carmignani G
J Urol; 2009 Nov; 182(5):2285-90. PubMed ID: 19762048
[TBL] [Abstract][Full Text] [Related]
5. Lymphocele prevention after pelvic laparoscopic lymphadenectomy by a collagen patch coated with human coagulation factors: a matched case-control study.
Tinelli A; Mynbaev OA; Tsin DA; Giorda G; Malvasi A; Guido M; Nezhat FR
Int J Gynecol Cancer; 2013 Jun; 23(5):956-63. PubMed ID: 23574881
[TBL] [Abstract][Full Text] [Related]
6. Prevention of lymphocele in female pelvic lymphadenectomy by a collagen patch coated with the human coagulation factors: a pilot study.
Tinelli A; Giorda G; Manca C; Pellegrino M; Prudenzano R; Guido M; Dell'Edera D; Malvasi A
J Surg Oncol; 2012 Jun; 105(8):835-40. PubMed ID: 21987409
[TBL] [Abstract][Full Text] [Related]
7. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.
Onda T; Tanaka YO; Kitai S; Manabe T; Ishikawa M; Hasumi Y; Miyamoto K; Ogawa G; Satoh T; Saito T; Kasamatsu T; Nakanishi T;
Jpn J Clin Oncol; 2021 Feb; 51(2):205-212. PubMed ID: 33556170
[TBL] [Abstract][Full Text] [Related]
8. Prospective Randomized Controlled Trial Exploring the Effect of TachoSil on Lymphocele Formation After Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Buelens S; Van Praet C; Poelaert F; Van Huele A; Decaestecker K; Lumen N
Urology; 2018 Aug; 118():134-140. PubMed ID: 29775698
[TBL] [Abstract][Full Text] [Related]
9. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
[TBL] [Abstract][Full Text] [Related]
10. A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial.
Grimm C; Polterauer S; Helmy S; Cibula D; Zikan M; Reinthaller A; Tempfer C
BMC Cancer; 2014 Aug; 14():635. PubMed ID: 25175029
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis.
Navarro-Rodríguez E; Gómez-Luque I; Díaz-Jiménez N; Rioja-Torres P; Bascuñana-Estudillo G; Ruiz-Rabelo JF; Ciria-Bru R; Álvarez-Benito M; Rufián-Peña S; Briceño-Delgado J
Am J Surg; 2014 Nov; 208(5):824-830. PubMed ID: 24881016
[TBL] [Abstract][Full Text] [Related]
12. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy.
Buda A; Fruscio R; Pirovano C; Signorelli M; Betti M; Milani R
Int J Gynaecol Obstet; 2012 Jun; 117(3):217-9. PubMed ID: 22424660
[TBL] [Abstract][Full Text] [Related]
13. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
[TBL] [Abstract][Full Text] [Related]
14. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma.
Lee EYP; An H; Perucho JAU; Chiu KWH; Hui ES; Chu MMY; Ngan HYS
Eur Radiol; 2020 Oct; 30(10):5551-5559. PubMed ID: 32405751
[TBL] [Abstract][Full Text] [Related]
15. [Does the use of TachoSil allow to reduce the morbidity of axillary dissection?].
Lacoste C; Ouldamer L; Body G; Marret H
Gynecol Obstet Fertil; 2013 Feb; 41(2):141-3. PubMed ID: 23375637
[TBL] [Abstract][Full Text] [Related]
16. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
Sørensen SM; Schnack TH; Høgdall C
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
[TBL] [Abstract][Full Text] [Related]
17. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
19. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
[TBL] [Abstract][Full Text] [Related]
20. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
